Perspectives of Fc engineered antibodies in CD19 targeting immunotherapies in pediatric B-cell precursor acute lymphoblastic leukemia

CD19 immunotherapies based on T cells opened new avenues in the treatment of pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL). However, Fc engineered CD19 antibodies may also bear great potential. In light of recent preclinical and clinical data, perspectives of such antibodies desi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kellner, Christian, Peipp, Matthias, Gramatzki, Martin, Schrappe, Martin, Schewe, Denis M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Point of View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6136853/
https://www.ncbi.nlm.nih.gov/pubmed/30221037
http://dx.doi.org/10.1080/2162402X.2018.1448331
_version_ 1783355081228288000
author Kellner, Christian
Peipp, Matthias
Gramatzki, Martin
Schrappe, Martin
Schewe, Denis M.
author_facet Kellner, Christian
Peipp, Matthias
Gramatzki, Martin
Schrappe, Martin
Schewe, Denis M.
author_sort Kellner, Christian
collection PubMed
description CD19 immunotherapies based on T cells opened new avenues in the treatment of pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL). However, Fc engineered CD19 antibodies may also bear great potential. In light of recent preclinical and clinical data, perspectives of such antibodies designed for improved effectiveness in BCP-ALL are presented.
format Online
Article
Text
id pubmed-6136853
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-61368532018-09-14 Perspectives of Fc engineered antibodies in CD19 targeting immunotherapies in pediatric B-cell precursor acute lymphoblastic leukemia Kellner, Christian Peipp, Matthias Gramatzki, Martin Schrappe, Martin Schewe, Denis M. Oncoimmunology Point of View CD19 immunotherapies based on T cells opened new avenues in the treatment of pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL). However, Fc engineered CD19 antibodies may also bear great potential. In light of recent preclinical and clinical data, perspectives of such antibodies designed for improved effectiveness in BCP-ALL are presented. Taylor & Francis 2018-04-09 /pmc/articles/PMC6136853/ /pubmed/30221037 http://dx.doi.org/10.1080/2162402X.2018.1448331 Text en © 2018 The Author(s). Published with license by Taylor & Francis Group, LLC http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
spellingShingle Point of View
Kellner, Christian
Peipp, Matthias
Gramatzki, Martin
Schrappe, Martin
Schewe, Denis M.
Perspectives of Fc engineered antibodies in CD19 targeting immunotherapies in pediatric B-cell precursor acute lymphoblastic leukemia
title Perspectives of Fc engineered antibodies in CD19 targeting immunotherapies in pediatric B-cell precursor acute lymphoblastic leukemia
title_full Perspectives of Fc engineered antibodies in CD19 targeting immunotherapies in pediatric B-cell precursor acute lymphoblastic leukemia
title_fullStr Perspectives of Fc engineered antibodies in CD19 targeting immunotherapies in pediatric B-cell precursor acute lymphoblastic leukemia
title_full_unstemmed Perspectives of Fc engineered antibodies in CD19 targeting immunotherapies in pediatric B-cell precursor acute lymphoblastic leukemia
title_short Perspectives of Fc engineered antibodies in CD19 targeting immunotherapies in pediatric B-cell precursor acute lymphoblastic leukemia
title_sort perspectives of fc engineered antibodies in cd19 targeting immunotherapies in pediatric b-cell precursor acute lymphoblastic leukemia
topic Point of View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6136853/
https://www.ncbi.nlm.nih.gov/pubmed/30221037
http://dx.doi.org/10.1080/2162402X.2018.1448331
work_keys_str_mv AT kellnerchristian perspectivesoffcengineeredantibodiesincd19targetingimmunotherapiesinpediatricbcellprecursoracutelymphoblasticleukemia
AT peippmatthias perspectivesoffcengineeredantibodiesincd19targetingimmunotherapiesinpediatricbcellprecursoracutelymphoblasticleukemia
AT gramatzkimartin perspectivesoffcengineeredantibodiesincd19targetingimmunotherapiesinpediatricbcellprecursoracutelymphoblasticleukemia
AT schrappemartin perspectivesoffcengineeredantibodiesincd19targetingimmunotherapiesinpediatricbcellprecursoracutelymphoblasticleukemia
AT schewedenism perspectivesoffcengineeredantibodiesincd19targetingimmunotherapiesinpediatricbcellprecursoracutelymphoblasticleukemia

Ejemplares similares